CellCentric raises $120M Series C for p300/CBP inhibitor inobrodib in multiple myeloma, plans Phase 2/3 trial for accelerated ...

Regeneron is acquiring 23andMe through a court-supervised sale, following 23andMe's bankruptcy filing and recent struggles.

Apnimed's oral drug met the efficacy bar in the first of two Phase 3 studies in obstructive sleep apnea, the biotech said ...